S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:NMRD

Nemaura Medical (NMRD) Stock Price, News & Analysis

$0.08
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.08
$0.09
50-Day Range
$0.07
$0.10
52-Week Range
$0.07
$1.25
Volume
4,605 shs
Average Volume
23,607 shs
Market Capitalization
$2.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25

Nemaura Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,205.9% Upside
$4.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$14,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.17 out of 5 stars

NMRD stock logo

About Nemaura Medical Stock (NASDAQ:NMRD)

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NMRD Stock Price History

NMRD Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Acutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2M
See More Headlines
Receive NMRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NMRD
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.25
High Stock Price Target
$6.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+5,205.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3,017.00
Book Value
($0.41) per share

Miscellaneous

Free Float
16,877,000
Market Cap
$2.31 million
Optionable
Optionable
Beta
-0.09
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Dewan Fazlul Hoque Chowdhury Ph.D. (Age 51)
    Chairman, CEO, President and Principal Financial & Accounting Officer
    Comp: $338.58k
  • Dr. Arash Ghadar (Age 47)
    Chief Operating Officer
  • Mr. Jay L. Warner
    Head of U.S. Commercial Operations
  • Mr. Thomas Bendix Mortensen
    Head of E.U. Commercial Operations & Marketing
  • Ms. Samantha Sanders
    Global Head of Digital Programs

NMRD Stock Analysis - Frequently Asked Questions

Should I buy or sell Nemaura Medical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NMRD shares.
View NMRD analyst ratings
or view top-rated stocks.

What is Nemaura Medical's stock price target for 2024?

2 brokerages have issued 12-month target prices for Nemaura Medical's stock. Their NMRD share price targets range from $2.50 to $6.00. On average, they predict the company's share price to reach $4.25 in the next year. This suggests a possible upside of 5,205.9% from the stock's current price.
View analysts price targets for NMRD
or view top-rated stocks among Wall Street analysts.

How have NMRD shares performed in 2024?

Nemaura Medical's stock was trading at $0.2190 on January 1st, 2024. Since then, NMRD shares have decreased by 63.4% and is now trading at $0.0801.
View the best growth stocks for 2024 here
.

How were Nemaura Medical's earnings last quarter?

Nemaura Medical Inc. (NASDAQ:NMRD) posted its quarterly earnings data on Monday, February, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter.

Who are Nemaura Medical's major shareholders?

Nemaura Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Nemaura Medical?

Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMRD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners